Strong Ph II data for Cougar's abiratenone

US drug developer Cougar Biotechnology says that CB7630 (abiraterone  acetate) shows promising evidence of efficacy according to data from  ongoing Phase II trials.

Presented at the American Society of Clinical Oncologists' Genitourinary  Cancers Symposium, held in Orlando, Florida, findings from one trial  showed that, of 31 evaluable patients, 77% experienced a decline in  prostate specific antigen levels of more than 30%, 71% greater than 50%  and 26% over 90%. For these patients, the median time to PSA progression  has not yet been reached, with patients continuing to be treated for  over months.

Of the 33 evaluable subjects with tumor lesions, CB7630 treatment  resulted in partial radiological responses in eight patients, stable  disease in 13 and progressive disease in four; eight patients are  awaiting radiographic disease assessment.